RxDoctor Payments Data

Martin Moran, DO

Family Medicine · Dupont, PANPI 1952398828

Payments from drug & device makers

$2,263in general payments, 2019–2025

Across 31 payments — averaging $73.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$478
  • Novo Nordisk$280
  • Axsome Therapeutics, Inc.$224
  • Johnson & Johnson$173
  • AbbVie$169
  • Esperion Therapeutics, Inc.$140
  • plus $798 from 11 others

What the payments were for

  • Food & beverage$2,22898%
  • Education$352%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,263 in reported general payments places this provider in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$169,360
Medicare patients
390
Services billed
2,142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban238$153,754
JanuviaSitagliptin Phosphate52$69,117
Trelegy ElliptaFluticasone/Umeclidin/Vilanter68$60,814
OzempicSemaglutide35$46,980
XareltoRivaroxaban37$40,431
RybelsusSemaglutide25$38,163
JardianceEmpagliflozin44$34,945
TrulicityDulaglutide36$33,137
MounjaroTirzepatide32$33,006
TradjentaLinagliptin36$32,894
Janumet XrSitagliptin Phos/Metformin Hcl11$18,081
MyrbetriqMirabegron30$17,648
Fluticasone-SalmeterolFluticasone Propion/Salmeterol55$8,277
Tresiba Flextouch U-100Insulin Degludec21$8,134
Colesevelam Hcl39$7,191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Dilantin$35$156,462249 claims
MerckJanuvia, Janumet Xr$16$87,19863 claims
Novo NordiskOzempic, Rybelsus$280$85,14360 claims
Lilly USA, LLCTrulicity, Mounjaro$19$66,14368 claims
Johnson & JohnsonXarelto$173$40,43137 claims
AbbVieSynthroid$169$4,33970 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Dupont

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →